The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells

Experimental Cell Research

Volumn 317, Issue 18, 2011, Pages 2671-2682

  Hong, Seung Keun ^a   Kim, Jin Hwan ^a   Lin, Ming Fong ^b   Park, Jong In ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Androgen receptor; Differentiation; ERK1 2; Growth inhibition; Prostate cancer; Raf

Indexed keywords

ANDROGEN RECEPTOR; CELL MARKER; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 2A; MEMBRANE METALLOENDOPEPTIDASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; NEURON SPECIFIC ENOLASE; RAF PROTEIN; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F1;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL STRAIN LNCAP; DOWN REGULATION; ENZYME ACTIVITY; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR INTRINSIC ACTIVITY;

EID: 80053574588     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2011.08.008     Document Type: Article

References (60)

1. Shaul Y.D., Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochimica et Biophysica Acta 2007, 1773:1213-1226.
2. Roberts P.J., Der C.J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007, 26:3291-3310.
3. Gioeli D., Mandell J.W., Petroni G.R., Frierson H.F., Weber M.J. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Research 1999, 59:279-284.
4. Royuela M., Arenas M.I., Bethencourt F.R., Sanchez-Chapado M., Fraile B., Paniagua R. Regulation of proliferation/apoptosis equilibrium by mitogen-activated protein kinases in normal, hyperplastic, and carcinomatous human prostate. Human Pathology 2002, 33:299-306.
5. Uzgare A.R., Kaplan P.J., Greenberg N.M. Differential expression and/or activation of P38MAPK, erk1/2, and jnk during the initiation and progression of prostate cancer. The Prostate 2003, 55:128-139.
6. Kinkade C.W., Castillo-Martin M., Puzio-Kuter A., Yan J., Foster T.H., Gao H., Sun Y., Ouyang X., Gerald W.L., Cordon-Cardo C., Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. The Journal of Clinical Investigation 2008, 118:3051-3064.
7. Anwar K., Nakakuki K., Shiraishi T., Naiki H., Yatani R., Inuzuka M. Presence of ras oncogene mutations and human papillomavirus DNA in human prostate carcinomas. Cancer Research 1992, 52:5991-5996.
8. Shiraishi T., Muneyuki T., Fukutome K., Ito H., Kotake T., Watanabe M., Yatani R. Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations. Anticancer Research 1998, 18:2789-2792.
9. Cho N.Y., Choi M., Kim B.H., Cho Y.M., Moon K.C., Kang G.H. BRAF and KRAS mutations in prostatic adenocarcinoma. International Journal of Cancer 2006, 119:1858-1862.
10. Shen Y., Lu Y., Yin X., Zhu G., Zhu J. KRAS and BRAF mutations in prostate carcinomas of Chinese patients. Cancer Genetics and Cytogenetics 2010, 198:35-39.
11. Palanisamy N., Ateeq B., Kalyana-Sundaram S., Pflueger D., Ramnarayanan K., Shankar S., Han B., Cao Q., Cao X., Suleman K., Kumar-Sinha C., Dhanasekaran S.M., Chen Y.B., Esgueva R., Banerjee S., LaFargue C.J., Siddiqui J., Demichelis F., Moeller P., Bismar T.A., Kuefer R., Fullen D.R., Johnson T.M., Greenson J.K., Giordano T.J., Tan P., Tomlins S.A., Varambally S., Rubin M.A., Maher C.A., Chinnaiyan A.M. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nature Medicine 2010, 16:793-798.
12. Rochette-Egly C. Nuclear receptors: integration of multiple signalling pathways through phosphorylation. Cellular Signalling 2003, 15:355-366.
13. Heinlein C.A., Chang C. Androgen receptor in prostate cancer. Endocrine Reviews 2004, 25:276-308.
14. Balk S.P., Knudsen K.E. AR, the cell cycle, and prostate cancer. Nuclear Receptor Signaling 2008, 6:e001.
15. Eder I.E., Haag P., Bartsch G., Klocker H. Targeting the androgen receptor in hormone-refractory prostate cancer-new concepts. Future Oncology (London, England) 2005, 1:93-101.
16. Bonkhoff H. Neuroendocrine differentiation in human prostate cancer. Morphogenesis, proliferation and androgen receptor status. Annals of Oncology 2001, 12(Suppl 2):S141-S144.
17. Segawa N., Mori I., Utsunomiya H., Nakamura M., Nakamura Y., Shan L., Kakudo K., Katsuoka Y. Prognostic significance of neuroendocrine differentiation, proliferation activity and androgen receptor expression in prostate cancer. Pathology International 2001, 51:452-459.
18. Abrahamsson P.A. Neuroendocrine cells in tumour growth of the prostate. Endocrine-Related Cancer 1999, 6:503-519.
19. Yuan T.C., Veeramani S., Lin M.F. Neuroendocrine-like prostate cancer cells: neuroendocrine transdifferentiation of prostate adenocarcinoma cells. Endocrine-Related Cancer 2007, 14:531-547.
20. Sauer C.G., Roemer A., Grobholz R. Genetic analysis of neuroendocrine tumor cells in prostatic carcinoma. The Prostate 2006, 66:227-234.
21. Zhang X.Q., Kondrikov D., Yuan T.C., Lin F.F., Hansen J., Lin M.F. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells. Oncogene 2003, 22:6704-6716.
22. Huss W.J., Gregory C.W., Smith G.J. Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: association with tumor cell proliferation prior to recurrence. The Prostate 2004, 60:91-97.
23. Jongsma J., Oomen M.H., Noordzij M.A., Van Weerden W.M., Martens G.J., van der Kwast T.H., Schroder F.H., van Steenbrugge G.J. Androgen deprivation of the PC-310 [correction of prohormone convertase-310] human prostate cancer model system induces neuroendocrine differentiation. Cancer Research 2000, 60:741-748.
24. Wright M.E., Tsai M.J., Aebersold R. Androgen receptor represses the neuroendocrine transdifferentiation process in prostate cancer cells. Molecular Endocrinology (Baltimore Md) 2003, 17:1726-1737.
25. Yuan T.C., Veeramani S., Lin F.F., Kondrikou D., Zelivianski S., Igawa T., Karan D., Batra S.K., Lin M.F. Androgen deprivation induces human prostate epithelial neuroendocrine differentiation of androgen-sensitive LNCaP cells. Endocrine-Related Cancer 2006, 13:151-167.
26. Hong S.K., Yoon S., Moelling C., Arthan D., Park J.I. Noncatalytic function of ERK1/2 can promote Raf/MEK/ERK-mediated growth arrest signaling. The Journal of Biological Chemistry 2009, 284:33006-33018.
27. Grad J.M., Lyons L.S., Robins D.M., Burnstein K.L. The androgen receptor (AR) amino-terminus imposes androgen-specific regulation of AR gene expression via an exonic enhancer. Endocrinology 2001, 142:1107-1116.
28. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods (San Diego Calif) 2001, 25:402-408.
29. Patrikidou A., Vlachostergios P.J., Voutsadakis I.A., Hatzidaki E., Valeri R.M., Destouni C., Apostolou E., Daliani D., Papandreou C.N. Inverse baseline expression pattern of the NEP/neuropeptides and NFkappaB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells. Cancer Cell International 2011, 11:13.
30. Wu C., Huang J. Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin pathway is essential for neuroendocrine differentiation of prostate cancer. The Journal of Biological Chemistry 2007, 282:3571-3583.
31. Samuels M.L., Weber M.J., Bishop J.M., McMahon M. Conditional transformation of cells and rapid activation of the mitogen-activated protein kinase cascade by an estradiol-dependent human raf-1 protein kinase. Molecular and Cellular Biology 1993, 13:6241-6252.
32. Zhu J., Woods D., McMahon M., Bishop J.M. Senescence of human fibroblasts induced by oncogenic Raf. Genes & Development 1998, 12:2997-3007.
33. Fanton C.P., McMahon M., Pieper R.O. Dual growth arrest pathways in astrocytes and astrocytic tumors in response to Raf-1 activation. The Journal of Biological Chemistry 2001, 276:18871-18877.
34. Ravi R.K., Weber E., McMahon M., Williams J.R., Baylin S., Mal A., Harter M.L., Dillehay L.E., Claudio P.P., Giordano A., Nelkin B.D., Mabry M. Activated Raf-1 causes growth arrest in human small cell lung cancer cells. The Journal of Clinical Investigation 1998, 101:153-159.
35. Park J.I., Strock C.J., Ball D.W., Nelkin B.D. The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Molecular and Cellular Biology 2003, 23:543-554.
36. Arthan D., Hong S.K., Park J.I. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Letters 2010, 297:31-41.
37. Chen J., Fujii K., Zhang L., Roberts T., Fu H. Raf-1 promotes cell survival by antagonizing apoptosis signal-regulating kinase 1 through a MEK-ERK independent mechanism. Proceedings of the National Academy of Sciences of the United States of America 2001, 98:7783-7788.
38. Lazar D.F., Wiese R.J., Brady M.J., Mastick C.C., Waters S.B., Yamauchi K., Pessin J.E., Cuatrecasas P., Saltiel A.R. Mitogen-activated protein kinase kinase inhibition does not block the stimulation of glucose utilization by insulin. The Journal of Biological Chemistry 1995, 270:20801-20807.
39. Fischer A.M., Katayama C.D., Pages G., Pouyssegur J., Hedrick S.M. The role of erk1 and erk2 in multiple stages of T cell development. Immunity 2005, 23:431-443.
40. Shin S., Dimitri C.A., Yoon S.O., Dowdle W., Blenis J. ERK2 but not ERK1 induces epithelial-to-mesenchymal transformation via DEF motif-dependent signaling events. Molecular Cell 2010, 38:114-127.
41. Lin H.K., Altuwaijri S., Lin W.J., Kan P.Y., Collins L.L., Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. The Journal of Biological Chemistry 2002, 277:36570-36576.
42. Eder I.E., Hoffmann J., Rogatsch H., Schafer G., Zopf D., Bartsch G., Klocker H. Inhibition of LNCaP prostate tumor growth in vivo by an antisense oligonucleotide directed against the human androgen receptor. Cancer Gene Therapy 2002, 9:117-125.
43. Zegarra-Moro O.L., Schmidt L.J., Huang H., Tindall D.J. Disruption of androgen receptor function inhibits proliferation of androgen-refractory prostate cancer cells. Cancer Research 2002, 62:1008-1013.
44. Liao X., Tang S., Thrasher J.B., Griebling T.L., Li B. Small-interfering RNA-induced androgen receptor silencing leads to apoptotic cell death in prostate cancer. Molecular Cancer Therapeutics 2005, 4:505-515.
45. Rodriguez-Gonzalez A., Cyrus K., Salcius M., Kim K., Crews C.M., Deshaies R.J., Sakamoto K.M. Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer. Oncogene 2008, 27:7201-7211.
46. Wu H.C., Hsieh J.T., Gleave M.E., Brown N.M., Pathak S., Chung L.W. Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. International Journal of Cancer 1994, 57:406-412.
47. Guo Z., Yang X., Sun F., Jiang R., Linn D.E., Chen H., Chen H., Kong X., Melamed J., Tepper C.G., Kung H.J., Brodie A.M., Edwards J., Qiu Y. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Research 2009, 69:2305-2313.
48. Tepper C.G., Boucher D.L., Ryan P.E., Ma A.H., Xia L., Lee L.F., Pretlow T.G., Kung H.J. Characterization of a novel androgen receptor mutation in a relapsed CWR22 prostate cancer xenograft and cell line. Cancer Research 2002, 62:6606-6614.
49. Lin H.K., Wang L., Hu Y.C., Altuwaijri S., Chang C. Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. The EMBO Journal 2002, 21:4037-4048.
50. Agoulnik I.U., Bingman W.E., Nakka M., Li W., Wang Q., Liu X., Brown M., Weigel N.L. Target gene specific regulation of androgen receptor activity by p42/p44 MAPK. Molecular Endocrinology (Baltimore, Md) 2008, 22:2420-2432.
51. Ito H., Watanabe M., Kim Y.T., Takahashi K. Inhibition of rat liver cathepsins B and L by the peptide aldehyde benzyloxycarbonyl-leucyl-leucyl-leucinal and its analogues. Journal of Enzyme Inhibition and Medicinal Chemistry 2009, 24:279-286.
52. Tsubuki S., Saito Y., Tomioka M., Ito H., Kawashima S. Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. Journal of Biochemistry 1996, 119:572-576.
53. Ravi R.K., McMahon M., Yangang Z., Williams J.R., Dillehay L.E., Nelkin B.D., Mabry M. Raf-1-induced cell cycle arrest in LNCaP human prostate cancer cells. Journal of Cellular Biochemistry 1999, 72:458-469.
54. Chan Q.K., Lam H.M., Ng C.F., Lee A.Y., Chan E.S., Ng H.K., Ho S.M., Lau K.M. Activation of GPR30 inhibits the growth of prostate cancer cells through sustained activation of Erk1/2, c-jun/c-fos-dependent upregulation of p21, and induction of G(2) cell-cycle arrest. Cell Death and Differentiation 2010, 17:1511-1523.
55. Moro L., Arbini A.A., Marra E., Greco M. Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2. International Journal of Oncology 2007, 30:217-224.
56. Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. Premature senescence involving p53 and p16 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes & Development 1998, 12:3008-3019.
57. Michaloglou C., Vredeveld L.C., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M., Majoor D.M., Shay J.W., Mooi W.J., Peeper D.S. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724.
58. Park J.I., Powers J.F., Tischler A.S., Strock C.J., Ball D.W., Nelkin B.D. GDNF-induced leukemia inhibitory factor can mediate differentiation via the MEK/ERK pathway in pheochromocytoma cells derived from nf1-heterozygous knockout mice. Experimental Cell Research 2005, 303:79-88.
59. Kim E.J., Park J.I., Nelkin B.D. IFI16 is an essential mediator of growth inhibition, but not differentiation, induced by the leukemia inhibitory factor/JAK/STAT pathway in medullary thyroid carcinoma cells. The Journal of Biological Chemistry 2005, 280:4913-4920.
60. Jeong J.H., Wang Z., Guimaraes A.S., Ouyang X., Figueiredo J.L., Ding Z., Jiang S., Guney I., Kang G.H., Shin E., Hahn W.C., Loda M.F., Abate-Shen C., Weissleder R., Chin L. BRAF activation initiates but does not maintain invasive prostate adenocarcinoma. PloS one 2008, 3:e3949.